A benzimidazole compound and a preparation method and application thereof
By preparing benzimidazole compound A12, the issues of drug safety and efficacy in POI treatment were resolved, achieving precise repair of the ovarian microenvironment and providing a safe and efficient treatment option.
Patent Information
- Application Number
- CN202611454919.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-09-18
- Publication Date
- 2026-11-10
AI Technical Summary
Current technologies lack safe and effective drugs for treating early-onset ovarian insufficiency (POI), hormone replacement therapy carries the risk of endocrine disorders, and existing anti-inflammatory small molecule drugs are insufficient to precisely repair the ovarian microenvironment.
A benzimidazole compound was developed, and compound A12 was prepared by a synthetic route including benzimidazole condensation cyclization, saponification and amidation. It showed multi-target synergistic effects of anti-apoptosis, anti-inflammation, anti-aging and proliferative effects.
Compound A12 showed no significant toxicity to KGN cells at a concentration of 10 μM, but significantly inhibited the expression of apoptosis factor Bax and inflammatory factors, regulated anti-inflammatory factors and aging markers, and improved the ovarian microenvironment, providing a safe and efficient new candidate drug for targeted intervention of POI.
Smart Images

Figure CN123062437A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of biomedical technology, and in particular relates to a benzimidazole compound, its preparation method and application. Background Technology
[0002] Premature ovarian insufficiency (POI) is a common reproductive system dysfunction characterized by premature follicular atresia, excessive apoptosis of ovarian granulosa cells, and the accumulation of chronic inflammation and oxidative stress in the ovary. Clinically, it is often accompanied by a persistent decline in ovarian reserve, severely impacting the reproductive health of women of reproductive age. At the molecular level, imbalances in the cAMP signaling pathway exacerbate abnormal cell proliferation, accumulated oxidative damage, and persistent activation of chronic inflammation, thereby accelerating follicular development and aging. This mechanism is one of the key molecular factors driving the progression of POI.
[0003] Currently, hormone replacement therapy is the mainstream clinical intervention for POIs. While this therapy can improve patients' clinical symptoms in the short term, long-term use can easily lead to endocrine disorders and increase the risk of breast and uterine-related lesions. Furthermore, given the pathological overlap between POIs and inflammation and neurodegenerative diseases in terms of oxidative stress and inflammatory pathways, existing approved anti-inflammatory small molecule drugs and neuroprotective small molecule preparations for inflammation and neurodegenerative diseases, although theoretically promising, are difficult to precisely repair the ovarian microenvironment, thus limiting their clinical translational value.
[0004] Currently, there is a lack of safe and effective specific drug candidates for POI clinical intervention. Therefore, based on the pathological characteristics of the disease, the design, screening, and development of novel active compounds with low toxicity and side effects has become a key research direction in the field of POI targeted intervention in the past decade. Summary of the Invention
[0005] To address the aforementioned technical problems, this invention proposes a benzimidazole compound, its preparation method, and its applications.
[0006] To achieve the above objectives, the present invention provides the following technical solution: A benzimidazole compound, with the structural formula shown in formula (I): (I); Wherein, L is -C2H4- or -CF2-; The R is independently selected from , , , , , , , , , , , , , , , , , , , , , , , or One of them.
[0007] More preferably, the structural formula of the benzimidazole compound is shown in Formula A or Formula B: , AB; Wherein, R1 is independently selected from , , , , , , , , , , , , , or One of them; R2 is independently selected from , , , , , , , , , , , , , , , , or One of them.
[0008] Preferably, the compound of formula A comprises the following structure: .
[0009] Preferably, the compound of formula B comprises the following structure: .
[0010] A method for preparing a benzimidazole compound includes the following steps: (1) Using aryl aldehydes as raw materials, methyl 2,3-diaminobenzoate is reacted with benzimidazole condensation cyclization in a solvent to obtain intermediate A. Then, saponification reaction is carried out under alkaline conditions. After the reaction is completed, the pH is adjusted to weak acidity to obtain intermediate B. The aryl aldehyde compounds are ; (2) The intermediate B is subjected to an amidation reaction with an amine compound in the presence of a condensing agent and a base to obtain the benzimidazole compound shown in Formula I.
[0011] Preferably, the aryl aldehyde compound is (Compound 1) or (Compound 4); Beneficial effects: The synthetic routes for preparing the benzimidazole compounds shown in Formula A and Formula B in this invention are as follows: .
[0012] Where a represents the benzimidazole condensation cyclization reaction, b represents the acid precipitation following the saponification reaction, and c represents the amidation reaction.
[0013] Preferably, the benzimidazole condensation cyclization reaction in step (1) is carried out with sodium metabisulfite as a promoter, the reaction temperature is 80°C, and the reaction time is 16h.
[0014] Preferably, the solvent in step (1) is DMF.
[0015] More preferably, the intermediate A in step (1) is (Compound 2) or (Compound 5).
[0016] Preferably, the alkaline hydrolysis reagent used in the alkaline conditions described in step (1) is LiOH; The saponification reaction takes 4 hours.
[0017] Preferably, the pH adjustment in step (1) to be weakly acidic is to adjust the pH to 6 using dilute hydrochloric acid.
[0018] More preferably, the intermediate B in step (1) is (Compound 3) or (Compound 6).
[0019] Preferably, the amine compound in step (2) includes one of the following: 3-aminopyridazine, 5-amino-1,3-dimethylpyrazole, 2-aminothiazole, 2-(aminomethyl)naphthalene, 3-(aminomethyl)pyrazole, 3,5-difluorobenzylamine, 1-tert-butoxycarbonyl-4-aminomethylpiperidine, 2,6-dimethylaniline, 2-(aminomethyl)pyridine, benzylamine, 2-(aminomethyl)pyrimidine, 4-aminomethyltetrahydropyran, 5-aminobenzothiazole, cyclopropylamine, 2,6-dichlorobenzylamine, o-fluorobenzylamine, 3,4-difluorobenzylamine, 3-(imidazol-1-yl)propyl-1-amine, 3,4-dimethoxyphenethylamine, 4-fluoro-3-methylbenzylamine, 4-methylbenzylamine, and methyl 4-(aminomethyl)benzoate.
[0020] More preferably, the aryl aldehyde compound is When the amine compound is, it is one of 2,6-dimethylaniline, 2-(aminomethyl)pyridine, benzylamine, 2-(aminomethyl)pyrimidine, 4-aminomethyltetrahydropyran, 5-aminobenzothiazole, cyclopropylamine, 2,6-dichlorobenzylamine, o-fluorobenzylamine, 3,4-difluorobenzylamine, 3-(imidazol-1-yl)propyl-1-amine, 3,4-dimethoxyphenethylamine, 4-fluoro-3-methylbenzylamine, 4-methylbenzylamine, and methyl 4-(aminomethyl)benzoate.
[0021] More preferably, the aryl aldehyde compound is When the amine compound is selected, it is one of the following: 4-aminomethyltetrahydropyran, 3-(imidazol-1-yl)propyl-1-amine, 3,4-dimethoxyphenethylamine, 3-aminopyridazine, 2-(aminomethyl)pyridine, 5-amino-1,3-dimethylpyrazole, 2-aminothiazole, 3,4-difluorobenzylamine, benzylamine, cyclopropylamine, 2,6-dichlorobenzylamine, 2-(aminomethyl)naphthalene, 3-(aminomethyl)pyrazole, 4-fluoro-3-methylbenzylamine, 2-(aminomethyl)pyrimidine, 3,5-difluorobenzylamine, o-fluorobenzylamine, and 1-tert-butoxycarbonyl-4-aminomethylpiperidine.
[0022] Preferably, the condensing agent in step (2) is 2-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethylurea hexafluorophosphate; The base is N,N-diisopropylethylamine.
[0023] Preferably, the amidation reaction in step (2) takes 4 hours.
[0024] The application of a benzimidazole compound in the preparation of a drug for treating early-onset ovarian hypoplasia.
[0025] Compared with the prior art, the present invention has the following advantages and technical effects: The benzimidazole compounds of Formula I prepared in this invention have a simple synthetic route, high yield, and readily available raw materials. Cytotoxicity experiments showed that most compounds exhibited no significant toxicity to KGN cells at a concentration of 10 μM, demonstrating good safety. Furthermore, anti-apoptotic activity screening revealed that compound A12 showed the best activity. Further mechanistic studies of this invention showed that compound A12 inhibited the expression of apoptosis factor Bax and inflammatory factors IL-1β and IL-6 in a concentration-dependent manner, while upregulating anti-inflammatory factors IL-4 and IL-10, inhibiting Caspase3 and Bax expression, significantly reducing the expression of aging markers CDKN1A and CDKN2A, restoring LAMP2 levels and the positive rate of aging-related β-galactosidase staining, and promoting PCNA expression. Through multi-target synergistic effects of anti-inflammation, anti-apoptosis, anti-aging, and proliferative effects, the compounds of this invention can effectively improve the ovarian microenvironment, providing a safe and efficient novel candidate drug for targeted intervention in POIs. Attached Figure Description
[0026] The accompanying drawings, which form part of this invention, are used to provide a further understanding of the invention. The illustrative embodiments of the invention and their descriptions are used to explain the invention and do not constitute an undue limitation of the invention. In the drawings: Figure 1 The results of toxicity tests on KGN cells for compounds A1-A15 and compounds B1-B18 obtained in Examples 1-33 are shown. Figure 2 The results show the inhibitory effects of compounds A3, A4, A10-A15 and compounds B1-B4 and B6-B18 obtained in Examples 3, 4 and 10-33 on Bax mRNA levels in KGN cells. Figure 3 The results of the toxicity test of compound A12 obtained in Example 12 on KGN cells at different concentrations are shown. Figure 4 The anti-inflammatory and anti-apoptotic IC50 of compound 12 obtained in Example 12 50 ; Wherein, A, B, and C represent the expression levels of Bax, IL-1β, and IL-6 in KGN cells stimulated with cyclophosphamide after treatment with compound A12, respectively; Figure 5 The expression levels of IL-4 (A), IL-10 (B), IL-6 (C) and IL-1β (D) in KGN cells stimulated with cyclophosphamide after treatment with compound A12 obtained in Example 12; Figure 6 The expression levels of Caspase3 (A) and Bax (B) in KGN cells stimulated with cyclophosphamide after treatment with compound A12 obtained in Example 12; Figure 7The results of the anti-aging ability test of compound A12 obtained in Example 12; In this table, A, B, and C represent the expression levels of CDKN1A, CDKN2A, and LAMP2 in KGN cells stimulated with cyclophosphamide after treatment with compound A12, respectively; D and E represent the senescence staining and corresponding positive statistical results of KGN cells stimulated with cyclophosphamide after treatment with compound A12, respectively. Figure 8 The results show the effect of compound A12 obtained in Example 12 on PCNA protein expression in KGN cells; In this image, A is an immunofluorescence image; B is a fluorescence statistical graph. Detailed Implementation
[0027] The technical solutions of the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.
[0028] To make the above-mentioned objects, features and advantages of the present invention more apparent and understandable, the present invention will be further described in detail below with reference to the accompanying drawings and specific embodiments.
[0029] Unless otherwise specified, all raw materials used in the embodiments of this invention were purchased through commercial channels; Among them, human ovarian granulosa cells KGN were purchased from Wuhan Pronosei Life Technology Co., Ltd.; The CAS number for compound 1 is 29668-44-8; The CAS number for compound 4 is 656-42-8; Unless otherwise specified, room temperature or normal temperature in the embodiments of the present invention refers to 25±3℃.
[0030] Examples 1-15 below illustrate the preparation of compounds A1-A15, using the following synthetic route: Example 1 A method for preparing a benzimidazole compound (compound A1) includes the following steps: (1) Synthesis of Compound 2: Compound 1 (26.8 mmol, 1 equivalent) was dissolved in N,N-dimethylformamide (DMF), followed by the sequential addition of methyl 2,3-diaminobenzoate (26.8 mmol, 1 equivalent) and sodium metabisulfite (Na2S2O5, 32.2 mmol, 1.2 equivalent) to obtain a mixture. The mixture was stirred at 80 °C for 16 hours to carry out a condensation cyclization reaction, and the reaction progress was monitored by thin-layer chromatography (TLC). After the reaction was completed, the system was cooled to room temperature and quenched with saturated ammonium chloride solution. The resulting aqueous phase was extracted three times with ethyl acetate to separate the organic phase, which was then washed three times with saturated sodium chloride solution and dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure to obtain the crude product. The crude product was purified by column chromatography using PE / EA as the eluent to obtain compound 2 (23.85 mmol) as a white solid, with a yield of 89%.
[0031] Compound 2 was identified using nuclear magnetic resonance spectroscopy and mass spectrometry, and the results were as follows: 1 H NMR (500 MHz, DMSO- d 6) d 12.20 (s, 1H), 7.93 (dd, J = 8.0, 1.0 Hz, 1H),7.88 (d, J = 2.0 Hz, 1H), 7.85-7.77 (m, 2H), 7.31 (t, J = 8.0 Hz, 1H), 7.03 (d, J =8.5 Hz, 1H), 4.34 (s, 4H), 3.98 (s, 3H). ESI-HRMS m / z: Calculated value is C 17 H 15 N2O4 + [M +H] + , 311.1026; The measured value is 311.1029.
[0032] (2) Synthesis of compound 3: Compound 2 (18.0 mmol, 1 equivalent) obtained in step (1) was dissolved in an ethanol / water mixture (20 mL, ethanol to water volume ratio 4:1), and lithium hydroxide (LiOH, 72.0 mmol, 4.0 equivalent) was added. The resulting mixture was stirred at room temperature for 4 hours to carry out ester hydrolysis, and the reaction progress was monitored by thin-layer chromatography (TLC). After the reaction was completed, most of the solvent was removed by vacuum distillation, and the resulting residue was diluted 10 times with water and the pH was adjusted to 6 with 1 M dilute hydrochloric acid. At this time, a large amount of solid precipitated. After filtration and drying of the filter cake, a white solid compound 3 (17.89 mmol) was obtained, with a yield of 99%.
[0033] Compound 3 was identified using nuclear magnetic resonance spectroscopy and mass spectrometry, and the results were as follows: 1 H NMR (500 MHz, DMSO- d 6) d 7.93-7.88 (m, 2H), 7.86-7.81 (m, 2H), 7.37 (t, J = 8.0 Hz, 1H), 7.05 (d, J = 8.5 Hz, 1H), 4.34 (t, J = 4.0 Hz, 4H), NH (not observed, 1H), OH (not observed, 1H). ESI-HRMS m / z: Calculated value is C 16 H 13 N2O4 + [M + H] + ,297.0869; The measured value is 297.0869.
[0034] (3) Synthesis of compound A1: Compound 3 (0.2 mmol, 1 equivalent) obtained in step (2) was dissolved in DMF, and 2-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethylurea hexafluorophosphate (HATU, 0.24 mmol, 1.2 equivalent), amine compound (2,6-dimethylaniline, 0.22 mmol, 1.1 equivalent) and N,N-diisopropylethylamine (DIPEA, 0.4 mmol, 2.0 equivalent) were added sequentially. The resulting mixture was stirred at room temperature for 4 hours to carry out amidation reaction, and the reaction progress was monitored by thin-layer chromatography (TLC). After the reaction was completed, the reaction was quenched with saturated ammonium chloride solution. The resulting aqueous phase was extracted three times with ethyl acetate to separate the organic phase. The resulting organic phase was then washed three times with saturated sodium chloride solution and dried with anhydrous sodium sulfate. The solvent was removed under reduced pressure to obtain the crude product. The crude product was purified by column chromatography using PE / EA as the eluent to obtain the target compound A1 with a yield of 88%.
[0035] The obtained compound A1 was identified using nuclear magnetic resonance spectroscopy and mass spectrometry, and the results were as follows: 1 H NMR (400 MHz, DMSO- d 6) d 13.38 (s, 1H), 11.46 (s, 1H), 7.95 (d, J = 7.6Hz, 1H), 7.82-7.71 (m, 3H), 7.39 (t, J = 7.6 Hz, 1H), 7.21-7.12 (m, 3H), 7.07 (d, J = 8.0 Hz, 1H), 4.32 (s, 4H), 2.30 (s, 6H). 13 C NMR (101 MHz, DMSO- d 6) d 163.6, 151.7, 147.4, 144.2, 135.5 (2×C), 135.4, 135.3, 134.5, 128.3 (2×C), 127.1, 124.4, 124.1, 122.1, 121.9, 118.8, 118.4, 117.4, 116.6, 65.0, 64.5, 18.8 (2×C). ESI-HRMS m / z: Calculated value is C. 24 H 22 N3O3 + [M + H] +, 400.1656; The measured value is 400.1659.
[0036] Example 2 A method for preparing a benzimidazole compound (compound A2) differs from Example 1 only in that the amine compound in step (3) is replaced with an equimolar amount of 2-(aminomethyl)pyridine, yielding a white solid compound A2 with a yield of 83%.
[0037] The obtained compound A2 was identified using nuclear magnetic resonance spectroscopy and mass spectrometry, and the results were as follows: 1 H NMR (400 MHz, DMSO- d 6) d 10.87 (t, J = 5.2 Hz, 1H), 8.73 (dt, J = 4.8,1.6 Hz, 1H), 7.95 (d, J = 2.0 Hz, 1H), 7.92-7.81 (m, 3H), 7.71 (dd, J = 8.0, 1.2Hz, 1H), 7.54 (d, J = 8.0 Hz, 1H), 7.40 (ddd, J = 7.6, 4.8, 1.2 Hz, 1H), 7.34 (t, J = 7.6 Hz, 1H), 7.11 (d, J = 8.4 Hz, 1H), 4.85 (d, J = 5.2 Hz, 2H), 4.36 (s, 4H), NH (not observed, 1H). 13 C NMR (101 MHz, DMSO- d 6) d 166.1, 155.6, 152.1, 146.9, 145.4, 144.2, 143.1, 138.7, 135.1, 125.4, 125.3, 123.6, 123.4, 121.7, 121.1, 120.6, 118.2, 117.1, 116.3, 64.9, 64.5, 42.1. ESI-HRMS m / z: Calculated value is C 22 H 19 N4O3 + [M + H] +, 387.1452; The measured value is 387.1456.
[0038] Example 3 A method for preparing a benzimidazole compound (compound A3) differs from Example 1 only in that the amine compound in step (3) is replaced with an equimolar amount of benzylamine, resulting in a white solid compound A3 with a yield of 74%.
[0039] The obtained compound A3 was identified using nuclear magnetic resonance spectroscopy and mass spectrometry, and the results were as follows: 1 H NMR (400 MHz, DMSO- d 6) d 13.27 (s, 1H), 10.42 (t, J = 5.6 Hz, 1H), 7.90 (dd, J = 7.6, 1.2 Hz, 1H), 7.74 (d, J = 2.0 Hz, 1H), 7.70 (ddd, J = 8.4, 2.8, 1.6Hz, 2H), 7.51-7.43 (m, 2H), 7.38 (dd, J = 8.4, 6.8 Hz, 2H), 7.34 (t, J = 7.6 Hz, 1H), 7.32-7.26 (m, 1H), 7.05 (d, J = 8.4 Hz, 1H), 4.73 (d, J = 5.6 Hz, 2H), 4.32 (s, 4H). 13 C NMR (101 MHz, DMSO- d 6) d 165.0, 151.5, 147.4, 144.2, 139.8, 135.8, 134.4, 128.9 (2×C), 127.7 (2×C), 127.4, 124.3, 123.8, 122.1, 121.8, 118.9, 118.3, 117.4, 116.3, 65.0, 64.5, 43.1. ESI-HRMS m / z: Calculated value is C. 23 H 20 N3O3 + [M +H] + , 386.1499; The measured value is 386.1496.
[0040] Example 4 A method for preparing a benzimidazole compound (compound A4) differs from Example 1 only in that the amine compound in step (3) is replaced with an equimolar amount of 2-(aminomethyl)pyrimidine, yielding a pale yellow solid compound A4 with a yield of 88%.
[0041] The obtained compound A4 was identified using nuclear magnetic resonance spectroscopy and mass spectrometry, and the results were as follows: 1 H NMR (400 MHz, DMSO- d 6) d 13.29 (s, 1H), 11.07 (s, 1H), 8.92 (d, J = 4.8Hz, 2H), 8.02 (d, J = 2.0 Hz, 1H), 7.93-7.84 (m, 2H), 7.71 (dd, J = 8.0, 1.2 Hz,1H), 7.50 (t, J = 4.8 Hz, 1H), 7.34 (t, J = 7.6 Hz, 1H), 7.13 (d, J = 8.4 Hz, 1H), 4.91 (d, J = 4.8 Hz, 2H), 4.36 (s, 4H). 13 C NMR (101 MHz, DMSO- d 6) d 166.8, 165.1, 157.9 (2×C), 151.7, 147.2, 144.2, 137.2, 134.6, 123.9, 123.6, 121.8, 121.7, 120.5, 119.8, 118.3, 117.3, 116.1, 65.0, 64.6, 46.1. ESI-HRMS m / z: Calculated value is C. 21 H 18 N5O3 + [M + H] + , 388.1404; The measured value is 388.1402.
[0042] Example 5 A method for preparing a benzimidazole compound (compound A5) differs from Example 1 only in that the amine compound in step (3) is replaced with an equimolar amount of 4-aminomethyltetrahydropyran, yielding a white solid compound A5 with a yield of 75%.
[0043] The obtained compound A5 was identified using nuclear magnetic resonance spectroscopy and mass spectrometry, and the results were as follows: 1 H NMR (400 MHz, DMSO- d 6) d 13.26 (s, 1H), 10.06 (t, J = 5.6 Hz, 1H), 7.84 (d, J = 7.6 Hz, 1H), 7.72 (d, J = 8.8 Hz, 2H), 7.68 (d, J = 8.0 Hz, 1H), 7.32 (t, J =7.6 Hz, 1H), 7.08 (d, J = 8.0 Hz, 1H), 4.34 (s, 4H), 4.00-3.80 (m, 2H), 3.40 (t, J = 6.0 Hz, 2H), 3.33 (td, J = 11.6, 2.0 Hz, 2H), 1.86 (ttd, J = 10.8, 6.8, 3.2Hz, 1H), 1.80-1.65 (m, 2H), 1.38 (qd, J = 12.0, 4.4 Hz, 2H). 13 C NMR (101 MHz, DMSO- d 6) d 165.0, 151.3, 147.6, 144.2, 134.6, 134.0, 124.5, 123.9, 122.3, 122.1, 122.0, 118.3, 117.6, 116.2, 67.2 (2×C), 65.0, 64.6, 45.2, 35.4, 31.0 (2×C). ESI-HRMS m / z: Calculated value is C. 22 H 24 N3O4 + [M + H] + , 394.1761; The measured value is 394.1758.
[0044] Example 6 A method for preparing a benzimidazole compound (compound A6) differs from Example 1 only in that the amine compound in step (3) is replaced with an equimolar amount of 5-aminobenzothiazole, yielding a white solid compound A6 with a yield of 81%.
[0045] The obtained compound A6 was identified using nuclear magnetic resonance spectroscopy and mass spectrometry, and the results were as follows: 1 H NMR (400 MHz, DMSO- d 6) d 13.37 (s, 1H), 12.39 (s, 1H), 9.31 (s, 1H), 8.87 (d, J = 2.0 Hz, 1H), 8.14 (d, J = 8.8 Hz, 1H), 7.97 (d, J = 7.6 Hz, 1H), 7.84 (dd, J = 8.4, 2.0 Hz, 1H), 7.81-7.70 (m, 3H), 7.37 (t, J = 7.6 Hz, 1H), 7.12 (d, J = 8.4 Hz, 1H), 4.35 (s, 4H). 13 C NMR (101 MHz, DMSO- d 6) d 163.9, 155.5, 151.3, 150.0, 148.0, 144.2, 136.9, 134.7, 133.7, 124.9, 124.7, 123.4, 122.5, 122.1, 120.1, 120.0, 118.4, 117.7, 117.6, 113.2, 113.1, 65.0, 64.5. ESI-HRMS m / z: Calculated value is C 23 H 17 N4O3S + [M + H] + , 429.1016; The measured value is 429.1012.
[0046] Example 7 A method for preparing a benzimidazole compound (compound A7) differs from Example 1 only in that the amine compound in step (3) is replaced with an equimolar amount of cyclopropylamine, yielding a white solid compound A7 with a yield of 83%.
[0047] The obtained compound A7 was identified using nuclear magnetic resonance spectroscopy and mass spectrometry, and the results were as follows: 1 H NMR (400 MHz, DMSO- d 6) d 13.24 (s, 1H), 10.00 (s, 1H), 7.83 (d, J = 7.6Hz, 1H), 7.76-7.61 (m, 3H), 7.31 (t, J = 7.6 Hz, 1H), 7.08 (d, J = 8.8 Hz, 1H), 4.34 (s, 4H), 2.97 (tq, J = 7.6, 4.0 Hz, 1H), 0.95-0.79 (m, 2H), 0.64 (dt, J =6.8, 4.4 Hz, 2H). 13 C NMR (101 MHz, DMSO- d 6) d 166.2, 151.3, 147.6, 144.2, 134.7, 134.1, 124.4, 123.8, 122.3, 121.9, 121.8, 118.4, 117.5, 116.3, 65.0, 64.5, 23.2, 6.5 (2×C). ESI-HRMS m / z: Calculated value is C. 19 H 18 N3O3 + [M + H] + , 336.1343; The measured value is 336.1346.
[0048] Example 8 A method for preparing a benzimidazole compound (compound A8) differs from Example 1 only in that the amine compound in step (3) is replaced with an equimolar amount of 2,6-dichlorobenzylamine, yielding a white solid compound A8 with a yield of 81%.
[0049] The obtained compound A8 was identified using nuclear magnetic resonance spectroscopy and mass spectrometry, and the results were as follows: 1 H NMR (400 MHz, DMSO- d 6) d 13.25 (s, 1H), 10.49 (t, J= 5.6 Hz, 1H), 7.86 (dd, J = 7.6, 1.2 Hz, 1H), 7.72-7.65 (m, 2H), 7.62 (dd, J = 8.4, 2.0 Hz, 1H),7.55 (d, J = 8.0 Hz, 2H), 7.39 (dd, J = 8.8, 7.6 Hz, 1H), 7.32 (t, J = 7.6 Hz, 1H), 7.05 (d, J = 8.4 Hz, 1H), 4.97 (d, J = 5.6 Hz, 2H), 4.34 (s, 4H). 13 C NMR (101 MHz, DMSO- d 6) d 164.7, 151.6, 147.1, 144.2, 135.9 (2×C), 134.6, 134.1, 134.1, 130.8, 129.2 (2×C), 123.8, 121.6, 121.6, 121.5, 119.9, 118.2, 117.0, 116.0, 65.0, 64.6, 39.3.
[0050] Example 9 A method for preparing a benzimidazole compound (compound A9) differs from Example 1 only in that the amine compound in step (3) is replaced with an equimolar amount of o-fluorobenzylamine, resulting in a pale yellow solid compound A9 with a yield of 90%.
[0051] The obtained compound A9 was identified using nuclear magnetic resonance spectroscopy and mass spectrometry, and the results were as follows: 1 H NMR (400 MHz, DMSO- d 6) d 13.28 (s, 1H), 10.42 (s, 1H), 7.87 (dd, J =7.6, 1.2 Hz, 1H), 7.76 (d, J = 2.0 Hz, 1H), 7.71 (ddd, J = 8.0, 3.2, 1.6 Hz, 2H),7.52 (td, J = 7.6, 1.6 Hz, 1H), 7.35 (qd, J= 7.6, 5.2 Hz, 2H), 7.23 (dtd, J =18.0, 8.0, 1.2 Hz, 2H), 7.06 (d, J = 8.4 Hz, 1H), 4.76 (d, J = 5.6 Hz, 2H), 4.34 (s, 4H). 13 C NMR (101 MHz, DMSO- d 6) d 165.1, 160.7 (d, J = 245.3 Hz, -CF), 151.6,147.5, 144.2, 135.9, 134.3, 130.0 (d, J = 4.3 Hz), 129.6 (d, J = 8.3 Hz), 126.4 (d, J = 14.8 Hz), 124.9 (d, J = 3.3 Hz), 124.3, 123.9, 122.1, 121.6, 118.9,118.3, 117.4, 116.4, 115.6 (d, J = 21.2 Hz), 65.0, 64.5, 37.1. ESI-HRMS m / z: Calculated value is C 23 H 19 FN3O3 + [M + H] + , 404.1405; The measured value is 404.1405.
[0052] Example 10 A method for preparing a benzimidazole compound (compound A10) differs from Example 1 only in that the amine compound in step (3) is replaced with an equimolar amount of 3,4-difluorobenzylamine, to obtain a white solid compound A10 with a yield of 80%.
[0053] The obtained compound A10 was identified using nuclear magnetic resonance spectroscopy and mass spectrometry, and the results were as follows: 1 H NMR (400 MHz, DMSO- d 6) d 13.26 (s, 1H), 10.39 (t, J = 6.0 Hz, 1H), 7.88 (d, J= 7.6 Hz, 1H), 7.78-7.67 (m, 3H), 7.52-7.48 (m, 1H), 7.45-7.38 (m, 1H), 7.37-7.27 (m, 2H), 7.04 (d, J = 8.4 Hz, 1H), 4.71 (d, J = 5.6 Hz, 2H), 4.33 (s, 4H). 13 C NMR (101 MHz, DMSO- d 6) d 165.2, 151.6, 149.9 (dd, J = 246.4, 12.8 Hz, -CF), 149.0 (dd, J = 245.1, 12.4 Hz, -CF), 147.4, 144.2, 137.7 (dd, J = 8.9, 3.6Hz), 136.1, 134.5, 124.4 (dd, J = 8.9, 3.4 Hz), 124.2, 123.8, 122.1, 121.7,121.6, 119.1, 118.2, 117.4, 117.3 (dd, J = 110.4, 17.2 Hz), 116.4, 65.0, 64.5, 42.2. ESI-HRMS m / z: Calculated value is C 23 H 18 F2N3O3 + [M + H] + , 422.1311; The measured value is 422.1318.
[0054] Example 11 A method for preparing a benzimidazole compound (compound A11) differs from Example 1 only in that the amine compound in step (3) is replaced with an equimolar amount of 3-(imidazol-1-yl)propyl-1-amine, yielding a white solid compound A11 with a yield of 78%.
[0055] The obtained compound A11 was identified using nuclear magnetic resonance spectroscopy and mass spectrometry, and the results were as follows: 1 H NMR (400 MHz, DMSO- d 6) d13.26 (s, 1H), 9.95 (s, 1H), 8.41 (s, 1H), 7.89-7.82 (m, 1H), 7.82-7.74 (m, 2H), 7.70 (dd, J = 8.0, 1.2 Hz, 1H), 7.55 (d, J = 2.0 Hz, 1H), 7.32 (dd, J = 13.6, 6.0 Hz, 2H), 7.07 (d, J = 8.4 Hz, 1H), 4.34 (s, 4H), 4.23 (t, J = 7.2 Hz, 2H), 3.49 (q, J = 6.4 Hz, 2H), 2.17 (p, J = 6.8 Hz, 2H). 13 C NMR (101 MHz, DMSO- d 6) d 165.4, 151.7, 147.3, 144.2, 135.9, 134.6, 124.0, 123.7, 122.5, 122.0, 121.9, 121.9, 120.4, 119.5, 118.3, 117.3, 116.2, 65.0, 64.5, 47.1, 36.4, 30.3. ESI-HRMS m / z: Calculated value is C 22 H 22 N5O3 + [M + H] + ,404.1717; The measured value is 404.1720.
[0056] Example 12 A method for preparing a benzimidazole compound (compound A12) differs from Example 1 only in that the amine compound in step (3) is replaced with an equimolar amount of 3,4-dimethoxyphenylethylamine, yielding a white solid compound A12 with a yield of 73%.
[0057] The obtained compound A12 was identified using nuclear magnetic resonance spectroscopy and mass spectrometry, and the results were as follows: 1 H NMR (400 MHz, DMSO- d 6) d 13.20 (s, 1H), 9.97 (t, J = 5.6 Hz, 1H), 7.87 (d,J = 7.6 Hz, 1H), 7.70 (d, J = 2.0 Hz, 1H), 7.67 (d, J = 8.0 Hz, 1H), 7.59-7.47 (m, 1H), 7.31 (t, J = 7.6 Hz, 1H), 7.03 (d, J = 8.4 Hz, 1H), 6.93 (s, 1H), 6.86 (s, 2H), 4.34 (s, 4H), 3.76 (q, J = 6.4 Hz, 2H), 3.68 (s, 3H), 3.63 (s, 3H), 2.89 (t, J = 6.0 Hz, 2H). 13 C NMR (101 MHz, DMSO- d 6) d 164.9, 151.4, 149.1, 147.7, 147.4, 144.1, 135.7, 134.3, 132.2, 124.2, 123.7, 122.2, 122.1, 120.9, 118.9, 118.3, 117.3, 116.1, 112.9, 112.3, 65.0, 64.5, 55.8, 55.7, 41.1, 35.2. ESI-HRMS m / z: Calculated value is C 26 H 26 N3O5 + [M + H] + , 460.1867; The measured value is 460.1873.
[0058] Example 13 A method for preparing a benzimidazole compound (compound A13) differs from Example 1 only in that the amine compound in step (3) is replaced with an equimolar amount of 4-fluoro-3-methylbenzylamine, yielding a white solid compound A13 with a yield of 72%.
[0059] The obtained compound A13 was identified using nuclear magnetic resonance spectroscopy and mass spectrometry, and the results were as follows: 1 H NMR (400 MHz, DMSO- d 6) d 13.26 (s, 1H), 10.35 (t, J = 5.6 Hz, 1H), 7.88 (dd,J = 7.6, 1.2 Hz, 1H), 7.74-7.64 (m, 3H), 7.38 (dd, J = 7.6, 2.4 Hz, 1H),7.34 (t, J = 7.6 Hz, 1H), 7.31-7.27 (m, 1H), 7.13 (dd, J = 9.6, 8.4 Hz, 1H), 7.05 (d, J = 8.4 Hz, 1H), 4.66 (d, J = 5.6 Hz, 2H), 4.33 (s, 4H), 2.24 (d, J = 2.0 Hz, 3H). 13 C NMR (101 MHz, DMSO- d 6) d 164.9, 160.3 (d, J = 242.6 Hz, -CF), 151.4,147.7, 144.2, 135.6, 135.5 (d, J = 3.3 Hz), 134.1, 131.0 (d, J = 5.0 Hz), 127.0 (d, J = 8.2 Hz), 124.6, 124.6, 124.4, 124.0, 122.4, 121.7 (d, J = 4.0 Hz), 118.3,117.7, 116.5, 115.2 (d, J = 22.1 Hz), 65.0, 64.6, 42.5, 14.6. ESI-HRMS m / z: Calculated value is C 24 H 21 FN3O3 + [M + H] + , 418.1561; The measured value is 418.1565.
[0060] Example 14 A method for preparing a benzimidazole compound (compound A14) differs from Example 1 only in that the amine compound in step (3) is replaced with an equimolar amount of 4-methylbenzylamine, yielding a white solid compound A14 with a yield of 83%.
[0061] The obtained compound A14 was identified using nuclear magnetic resonance spectroscopy and mass spectrometry, and the results were as follows: 1 H NMR (400 MHz, DMSO- d 6) d 13.25 (s, 1H), 10.36 (s, 1H), 7.89 (dd, J =7.6, 1.2 Hz, 1H), 7.69 (ddd, J = 9.2, 7.2, 2.0 Hz, 3H), 7.39-7.30 (m, 3H), 7.19 (d, J = 8.0 Hz, 2H), 7.04 (d, J = 8.4 Hz, 1H), 4.66 (d, J = 5.6 Hz, 2H), 4.33 (s, 4H), 2.30 (s, 3H). 13 C NMR (101 MHz, DMSO- d 6) d 165.0, 151.5, 147.4, 144.2, 136.6, 136.6, 136.5, 134.4, 129.4 (2×C), 127.7 (2×C), 124.2, 123.7, 122.0, 121.9, 119.1, 118.3, 117.4, 116.2, 65.0, 64.6, 42.9, 21.1. ESI-HRMS m / z: Calculated value is C 24 H 22 N3O3 + [M + H] + , 400.1656; The measured value is 400.1659.
[0062] Example 15 A method for preparing a benzimidazole compound (compound A15) differs from Example 1 only in that the amine compound in step (3) is replaced with an equimolar amount of methyl 4-(aminomethyl)benzoate, yielding a pale yellow solid compound A15 with a yield of 70%.
[0063] The obtained compound A15 was identified using nuclear magnetic resonance spectroscopy and mass spectrometry, and the results were as follows: 1 H NMR (400 MHz, DMSO- d 6) d 13.27 (s, 1H), 10.45 (t, J= 6.0 Hz, 1H), 7.97 (d, J = 8.0 Hz, 2H), 7.88 (d, J = 7.6 Hz, 1H), 7.77-7.66 (m, 3H), 7.58 (d, J = 8.0Hz, 2H), 7.34 (t, J = 7.6 Hz, 1H), 7.03 (d, J = 8.4 Hz, 1H), 4.81 (d, J = 5.6 Hz, 2H), 4.32 (d, J = 2.4 Hz, 4H), 3.84 (s, 3H). 13 C NMR (101 MHz, DMSO- d 6) d 166.5, 165.2, 151.5, 147.6, 145.4, 144.1, 135.3, 134.2, 129.8 (2×C), 128.8, 127.8 (2×C), 124.5, 124.0, 122.3, 121.6, 118.4, 118.3, 117.7, 116.5, 65.0, 64.5, 52.4, 42.9. ESI-HRMS m / z: Calculated value is C. 25 H 22 N3O5 + [M + H] + , 444.1554; The measured value is 444.1558.
[0064] Examples 16-33 below describe the preparation of compounds B1-B18, using the following synthetic routes: Example 16 A method for preparing a benzimidazole compound (compound B1) includes the following steps: (1) Synthesis of Compound 5: Compound 4 (26.8 mmol, 1 equivalent) was dissolved in N,N-dimethylformamide (DMF), followed by the sequential addition of methyl 2,3-diaminobenzoate (26.8 mmol, 1 equivalent) and sodium metabisulfite (Na2S2O5, 32.2 mmol, 1.2 equivalent) to obtain a mixture. The mixture was stirred at 80 °C for 16 hours to carry out a condensation cyclization reaction, and the reaction progress was monitored by thin-layer chromatography (TLC). After the reaction was completed, the system was cooled to room temperature and quenched with saturated ammonium chloride solution. The resulting aqueous phase was extracted three times with ethyl acetate to separate the organic phase. The resulting organic phase was then washed three times with saturated sodium chloride solution and dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure to obtain the crude product. The crude product was purified by column chromatography using PE / EA as the eluent to obtain a white solid compound 5 (22.66 mmol), with a yield of 86%.
[0065] Compound 5 was identified using nuclear magnetic resonance spectroscopy and mass spectrometry, and the results were as follows: 1 H NMR (500 MHz, CD3OD) d 8.02-7.98 (m, 2H), 7.92 (dd, J = 7.5, 1.0 Hz,1H), 7.90 (dd, J = 8.0, 1.0 Hz, 1H), 7.41-7.37 (m, 1H), 7.36 (t, J = 8.0 Hz, 1H), 4.04 s, 3H, NH (not observed, 1H). ESI-HRMS m / z: Calculated value is C 16 H 11 F2N2O4 + [M + H] + , 333.0681; The measured value is 333.0678.
[0066] (2) Synthesis of compound 6: Compound 5 (18.0 mmol, 1 equivalent) obtained in step (1) was dissolved in an ethanol / water mixture (20 mL, ethanol to water volume ratio 4:1), and lithium hydroxide (LiOH, 72.0 mmol, 4.0 equivalent) was added. The resulting mixture was stirred at room temperature for 4 hours to carry out the saponification reaction, and the reaction progress was monitored by thin-layer chromatography (TLC). After the reaction was completed, most of the solvent was removed by vacuum distillation, and the resulting residue was diluted 10 times with water and the pH was adjusted to 6 with 1 M dilute hydrochloric acid. At this time, a large amount of solid precipitated. After filtration and drying of the filter cake, a white solid compound 6 (17.91 mmol) was obtained, with a yield of 99%.
[0067] Compound 6 was identified using nuclear magnetic resonance spectroscopy and mass spectrometry, and the results were as follows: 1 H NMR (500 MHz, DMSO- d 6) d 8.40 (d, J = 2.0 Hz, 1H), 8.26 (dd, J = 8.5, 2.0Hz, 1H), 7.92 (dd, J = 8.0, 1.0 Hz, 1H), 7.84 (dd, J = 7.5, 1.0 Hz, 1H), 7.60 (d, J = 8.5 Hz, 1H), 7.34 (t, J = 8.0 Hz, 1H), NH (not observed, 1H), OH (not observed, 1H). ESI-HRMS m / z: Calculated value is C 15 H9F2N2O4 + [M + H] + , 319.0525; The measured value is 319.0528.
[0068] (3) Synthesis of compound B1: Compound 6 (0.2 mmol, 1 equivalent) obtained in step (2) was dissolved in DMF, and 2-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethylurea hexafluorophosphate (HATU, 0.24 mmol, 1.2 equivalent), amine compound (4-aminomethyltetrahydropyran, 0.22 mmol, 1.1 equivalent) and N,N-diisopropylethylamine (DIPEA, 0.4 mmol, 2.0 equivalent) were added sequentially. The resulting mixture was stirred at room temperature for 4 hours to carry out amidation reaction, and the reaction progress was monitored by thin-layer chromatography (TLC). After the reaction was completed, the reaction was quenched with saturated ammonium chloride solution. The resulting aqueous phase was extracted three times with ethyl acetate to separate the organic phase. The resulting organic phase was then washed three times with saturated sodium chloride solution and dried with anhydrous sodium sulfate. The solvent was removed under reduced pressure to obtain the crude product. The crude product was purified by column chromatography using PE / EA as the eluent to obtain the target compound B1 with a yield of 78%.
[0069] The obtained compound B1 was identified using nuclear magnetic resonance spectroscopy and mass spectrometry, and the results were as follows: 1 H NMR (400 MHz, TFA- d ) d 8.32-8.00 (m, 3H), 7.95 (d, J = 6.4 Hz, 1H),7.90-7.67 (m, 1H), 7.37 (t, J = 7.6 Hz, 1H), 4.25 (d, J = 11.2 Hz, 2H), 3.90-3.41 (m, 4H), 2.09 (s, 1H), 1.85 (d, J = 13.2 Hz, 2H), 1.77-1.47 (m, 2H), NH (notobserved, 2H). 13 C NMR (101 MHz, TFA- d ) d 162.4, 146.0, 144.6, 140.9, 127.7,127.6 (t, J = 264.0 Hz, -CF2), 125.9, 122.9, 121.8, 120.7, 120.6, 114.0, 111.9, 106.5, 104.9, 63.0 (2×C), 41.5, 30.1, 25.1 (2×C). ESI-HRMS m / z: Calculated value is C 21 H 20F2N3O4 + [M + H] + , 416.1416; The measured value is 416.1418.
[0070] Example 17 A method for preparing a benzimidazole compound (compound B2) differs from Example 1 only in that the amine compound in step (3) is replaced with an equimolar amount of 3-(imidazol-1-yl)propyl-1-amine, yielding a pale yellow solid compound B2 with a yield of 72%.
[0071] The obtained compound B2 was identified using nuclear magnetic resonance spectroscopy and mass spectrometry, and the results were as follows: 1 H NMR (400 MHz, DMSO- d 6) d 13.45 (s, 1H), 9.85 (s, 1H), 8.26 (s, 1H), 8.10 (d, J = 8.4 Hz, 1H), 7.88 (d, J = 7.6 Hz, 1H), 7.72 (d, J = 4.4 Hz, 2H), 7.61 (d, J = 8.4 Hz, 1H), 7.34 (t, J = 7.6 Hz, 1H), 7.26 (s, 1H), 6.93 (s, 1H), 4.11 (t, J = 6.8 Hz, 2H), 3.45 (t, J = 6.4 Hz, 2H), 2.11 (p, J = 6.8 Hz, 2H). 13 C NMR (101MHz, DMSO- d 6) d 165.5, 151.1, 144.7, 143.8, 140.5, 136.1, 135.9, 131.7 (t, J =254.9 Hz, -CF2), 126.1, 124.3, 123.3, 123.1, 122.5, 122.3, 120.3, 116.0, 111.1, 109.4, 47.2, 36.4, 30.5. ESI-HRMS m / z: Calculated value is C 21 H 18 F2N5O3 + [M + H]+ ,426.1372; The measured value is 426.1370.
[0072] Example 18 A method for preparing a benzimidazole compound (compound B3) differs from Example 1 only in that the amine compound in step (3) is replaced with an equimolar amount of 3,4-dimethoxyphenylethylamine, yielding a pale yellow solid compound B3 with a yield of 71%.
[0073] The obtained compound B3 was identified using nuclear magnetic resonance spectroscopy and mass spectrometry, and the results were as follows: 1 H NMR (400 MHz, DMSO- d 6) d 13.42 (s, 1H), 9.84 (t, J = 6.0 Hz, 1H), 8.06 (s, 1H), 7.91 (t, J = 6.8 Hz, 2H), 7.72 (d, J = 8.0 Hz, 1H), 7.59 (d, J = 8.4 Hz, 1H), 7.36 (t, J = 7.6 Hz, 1H), 6.91 (s, 1H), 6.85 (s, 2H), 3.76 (q, J = 6.8 Hz, 2H), 3.66 (s, 3H), 3.61 (s, 3H), 2.89 (t, J = 6.8 Hz, 2H). 13 C NMR (101 MHz, DMSO- d 6) d 164.8, 150.7, 149.1, 147.7, 145.0, 143.7, 138.8, 135.3, 132.3, 131.7 (t, J = 255.3 Hz, -CF2), 124.8, 123.7, 123.6, 122.5, 122.4, 120.9, 116.0, 113.0, 112.2, 111.1, 109.5, 55.7, 55.6, 40.9, 35.3. ESI-HRMS m / z: Calculated value is C 25 H 22 F2N3O5 + [M + H] +, 482.1522; The measured value is 482.1524.
[0074] Example 19 A method for preparing a benzimidazole compound (compound B4) differs from Example 1 only in that the amine compound in step (3) is replaced with an equimolar amount of 3-aminopyridazine, yielding a white solid compound B4 with a yield of 83%.
[0075] The obtained compound B4 was identified using nuclear magnetic resonance spectroscopy and mass spectrometry, and the results were as follows: 1 H NMR (400 MHz, DMSO- d 6) d 13.48 (s, 1H), 12.87 (s, 1H), 9.00 (dd, J =4.8, 1.6 Hz, 1H), 8.54 (dd, J = 9.2, 1.6 Hz, 1H), 8.14-8.02 (m, 1H), 8.00 (d, J =2.4 Hz, 1H), 7.88 (d, J = 7.4 Hz, 1H), 7.72 (dd, J = 9.2, 4.8 Hz, 1H), 7.67 (d, J =8.0 Hz, 1H), 7.60 (d, J = 8.4 Hz, 1H), 7.30 (t, J = 7.6 Hz, 1H). 13 C NMR (101 MHz, DMSO- d 6) d 164.1, 156.2, 150.8, 147.3, 144.7, 143.5, 140.6, 135.3, 131.6 (t, J =255.1 Hz, -CF2), 130.9, 125.3, 123.9, 123.7, 123.1, 121.5, 120.3, 116.8, 110.9, 108.3. ESI-HRMS m / z: Calculated value is C 19 H 12 F2N5O3 + [M + H] + , 396.0903; The measured value is 396.0905.
[0076] Example 20 A method for preparing a benzimidazole compound (compound B5) differs from Example 1 only in that the amine compound in step (3) is replaced with an equimolar amount of 2-(aminomethyl)pyridine, yielding a white solid compound B5 with a yield of 71%.
[0077] The obtained compound B5 was identified using nuclear magnetic resonance spectroscopy and mass spectrometry, and the results were as follows: 1 H NMR (400 MHz, TFA- d ) d 8.58 (t, J = 7.3 Hz, 1H), 8.47 (q, J = 8.2 Hz, 1H), 8.08-7.96 (m, 2H), 7.92 (d, J = 8.2 Hz, 1H), 7.89-7.78 (m, 2H), 7.73 (d, J =7.3 Hz, 1H), 7.62 (q, J = 8.7, 8.2 Hz, 1H), 7.19 (t, J = 7.8 Hz, 1H), 5.04 (s, 2H), NH (not observed, 2H). 13 C NMR (101 MHz, TFA- d ) d 163.7, 147.8, 146.5,144.7, 143.9, 140.9, 137.1, 127.8, 127.6 (t, J = 259.7 Hz, -CF2), 125.9, 123.2, 122.3, 122.3, 121.9, 121.4, 115.0, 113.1, 111.8, 106.5, 105.0, 37.1. ESI-HRMSm / z: Calculated value is C 21 H 15 F2N4O3 + [M + H] + , 409.1107; The measured value is 409.1106.
[0078] Example 21 A method for preparing a benzimidazole compound (compound B6) differs from Example 1 only in that the amine compound in step (3) is replaced with an equimolar amount of 5-amino-1,3-dimethylpyrazole, yielding a white solid compound B6 with a yield of 78%.
[0079] The obtained compound B6 was identified using nuclear magnetic resonance spectroscopy and mass spectrometry, and the results were as follows: 1 H NMR (400 MHz, TFA- d ) d 8.09 (d, J = 7.6 Hz, 1H), 7.97 (d, J = 8.4 Hz, 1H), 7.83 (d, J = 8.4 Hz, 1H), 7.75 (s, 1H), 7.70-7.49 (m, 1H), 7.20 (d, J = 8.4Hz, 1H), 6.61 (s, 1H), 3.92 (s, 3H), 2.36 (s, 3H), NH (not observed, 2H). 13 CNMR (101 MHz, TFA- d ) d 160.9, 146.7, 144.8, 143.2, 141.0, 136.8, 127.9, 127.6 (t, J = 260.9 Hz, -CF2), 126.1, 123.1, 122.0, 121.9, 115.8, 112.7, 111.7, 106.6, 104.9, 98.5, 30.5, 5.4. ESI-HRMS m / z: Calculated value is C 20 H 16 F2N5O3 + [M + H] + ,412.1216; The measured value is 412.1215.
[0080] Example 22 A method for preparing a benzimidazole compound (compound B7) differs from Example 1 only in that the amine compound in step (3) is replaced with an equimolar amount of 2-aminothiazole, resulting in a pale yellow solid compound B7 with a yield of 82%.
[0081] The obtained compound B7 was identified using nuclear magnetic resonance spectroscopy and mass spectrometry, and the results were as follows: 1 H NMR (400 MHz, DMSO- d 6) d 13.45 (s, 1H), 13.18 (s, 1H), 8.07-7.89 (m, 2H), 7.86 (d, J = 7.6 Hz, 1H), 7.62 (s, 1H), 7.60-7.47 (m, 2H), 7.29 (d, J = 7.2Hz, 2H). 13 C NMR (101 MHz, DMSO- d 6) d 162.7, 158.2, 151.1, 144.8, 143.6, 140.3,137.5, 135.4, 131.6 (t, J = 255.3 Hz, -CF2), 125.1, 124.2, 123.8, 123.4, 119.3, 117.0, 114.4, 111.1, 108.7. Yield: 78%. ESI-HRMS m / z: Calculated value is C 18 H 11 F2N4O3S + [M+ H] + , 401.0514; The measured value is 401.0513.
[0082] Example 23 A method for preparing a benzimidazole compound (compound B8) differs from Example 1 only in that the amine compound in step (3) is replaced with an equimolar amount of 3,4-difluorobenzylamine, yielding a pale yellow solid compound B8 with a yield of 79%.
[0083] The obtained compound B8 was identified using nuclear magnetic resonance spectroscopy and mass spectrometry, and the results were as follows: 1 H NMR (400 MHz, DMSO- d 6) d 13.48 (s, 1H), 10.29 (s, 1H), 8.28 (s, 1H), 8.10 (d, J = 8.4 Hz, 1H), 7.89 (d, J = 7.6 Hz, 1H), 7.75 (d, J = 8.0 Hz, 1H), 7.62 (d, J= 8.4 Hz, 1H), 7.51-7.46 (m, 1H), 7.44-7.33 (m, 2H), 7.31-7.24 (m, 1H), 4.70 (d, J = 6.0 Hz, 2H). 13 C NMR (101 MHz, DMSO- d 6) d 165.2, 149.8 (dd, J = 246.5,12.6 Hz, -CF), 148.9 (dd, J = 245.2, 12.5 Hz, -CF), 145.1, 143.7, 138.6, 137.9,137.8 (dd, J = 8.8, 2.4 Hz), 135.5, 131.7 (t, J = 255.2 Hz, -CF2), 124.9, 124.8,124.3 (dd, J = 6.6, 3.3 Hz, -CF), 123.8, 123.7, 122.0, 122.0, 117.7 (dd, J =111.1, 17.4 Hz), 116.4, 111.1, 109.8, 42.2. ESI-HRMS m / z: Calculated value is C 22 H 14 F4N3O3 + [M + H] + , 444.0966; The measured value is 444.0965.
[0084] Example 24 A method for preparing a benzimidazole compound (compound B9) differs from Example 1 only in that the amine compound in step (3) is replaced with an equimolar amount of benzylamine, resulting in a gray solid compound B9 with a yield of 83%.
[0085] The obtained compound B9 was identified using nuclear magnetic resonance spectroscopy and mass spectrometry, and the results were as follows: 1 H NMR (500 MHz, DMSO- d 6) d 13.50 (s, 1H), 10.30 (t, J = 6.0 Hz, 1H), 8.22 (d, J = 1.6 Hz, 1H), 8.08 (dd,J = 8.4, 1.6 Hz, 1H), 7.92 (dd, J = 7.6, 1.2 Hz, 1H), 7.81-7.72 (m, 1H), 7.66 (d, J = 8.4 Hz, 1H), 7.47 (d, J = 7.2 Hz, 2H), 7.39 (td, J = 7.6, 5.6 Hz, 3H), 7.33-7.26 (m, 1H), 4.73 (d, J = 5.6 Hz, 2H). 13 C NMR (101 MHz, TFA-) d ) d 162.2, 146.1, 144.7, 141.0, 130.8, 127.8, 127.7 (t, J = 265.0Hz, -CF2), 126.0, 124.6 (2×C), 124.0, 123.1 (2×C), 121.9, 120.8, 114.6, 114.1, 112.1, 111.8, 106.5, 105.0, 40.5. ESI-HRMS m / z: Calculated value is C 22 H 16 F2N3O3 + [M+ H] + , 408.1154; The measured value is 408.1153.
[0086] Example 25 A method for preparing a benzimidazole compound (compound B10) differs from Example 1 only in that the amine compound in step (3) is replaced with an equimolar amount of cyclopropylamine, resulting in a gray solid compound B10 with a yield of 87%.
[0087] The obtained compound B10 was identified using nuclear magnetic resonance spectroscopy and mass spectrometry, and the results were as follows: 1 H NMR (400 MHz, DMSO- d 6) d 13.44 (s, 1H), 10.03-9.69 (m, 1H), 8.12 (s, 1H), 8.04 (d, J = 8.4 Hz, 1H), 7.87 (d, J = 7.6 Hz, 1H), 7.71 (d,J = 8.0 Hz, 1H), 7.63 (d, J = 8.4 Hz, 1H), 7.34 (t, J = 8.0 Hz, 1H), 2.97 (tq, J = 7.6, 4.0 Hz, 1H),0.83 (d, J = 7.4 Hz, 2H), 0.68 (p, J = 4.8 Hz, 2H). 13 C NMR (101 MHz, DMSO- d 6) d 166.1, 150.4, 145.5, 143.6, 135.9, 134.7, 131.7 (t, J = 255.6 Hz, -CF2), 125.7, 124.4, 123.9, 123.1, 122.0, 116.5, 111.2, 110.1, 23.2, 6.5 (2×C). ESI-HRMSm / z: Calculated value is C 18 H 14 F2N3O3 + [M + H] + , 358.0998; The measured value is 358.0997.
[0088] Example 26 A method for preparing a benzimidazole compound (compound B11) differs from Example 1 only in that the amine compound in step (3) is replaced with an equimolar amount of 2,6-dichlorobenzylamine, yielding a gray solid compound B11 with a yield of 70%.
[0089] The obtained compound B11 was identified using nuclear magnetic resonance spectroscopy and mass spectrometry, and the results were as follows: 1 H NMR (400 MHz, DMSO- d 6) d 13.51 (s, 1H), 10.35 (t, J = 5.6 Hz, 1H), 7.99 (d, J = 8.8 Hz, 2H), 7.89 (d, J = 7.6 Hz, 1H), 7.74 (d, J = 8.0 Hz, 1H), 7.66 (d, J=8.4 Hz, 1H), 7.56 (d, J = 8.0 Hz, 2H), 7.38 (dt, J = 14.0, 8.0 Hz, 2H), 4.96 (d, J = 5.4 Hz, 2H). 13 C NMR (101 MHz, DMSO- d 6) d 164.5, 150.7, 145.0, 143.7, 135.7 (2×C), 135.3, 134.4, 134.3, 131.7 (t, J = 255.1 Hz, -CF2), 130.8, 129.2 (2×C), 125.0, 124.6, 123.7, 121.9, 121.9, 116.1, 111.2, 109.1, 39.1. ESI-HRMS m / z: calculated value is C 22 H 14 Cl2F2N3O3 + [M + H] + , 476.0375; The measured value is 476.0378.
[0090] Example 27 A method for preparing a benzimidazole compound (compound B12) differs from Example 1 only in that the amine compound in step (3) is replaced with an equimolar amount of 2-(aminomethyl)naphthalene, yielding a white solid compound B12 with a yield of 86%.
[0091] The obtained compound B12 was identified using nuclear magnetic resonance spectroscopy and mass spectrometry, and the results were as follows: 1 H NMR (400 MHz, DMSO- d 6) d 13.49 (s, 1H), 10.40 (t, J = 5.6 Hz, 1H), 8.21 (s, 1H), 8.06 (d, J = 8.4 Hz, 1H), 7.95-7.86 (m, 5H), 7.76 (d, J = 8.0 Hz, 1H), 7.63 (d, J = 8.4 Hz, 1H), 7.57 (d, J = 8.4 Hz, 1H), 7.49 (q, J= 4.8 Hz, 2H), 7.39 (t, J = 7.6 Hz, 1H), 4.89 (d, J = 5.6 Hz, 2H). 13 C NMR (101 MHz, DMSO- d 6) d 165.0,150.7, 145.4, 143.6, 137.4, 136.9, 134.9, 133.4, 132.6, 131.7 (t, J = 255.6 Hz, -CF2), 128.5, 128.0, 127.9, 126.6, 126.4, 126.1, 125.8, 125.5, 124.3, 124.0, 123.6, 122.1, 116.6, 111.1, 110.1, 43.4. ESI-HRMS m / z: Calculated value is C 26 H 18 F2N3O3 + [M+ H] + , 458.1311; The measured value is 458.1308.
[0092] Example 28 A method for preparing a benzimidazole compound (compound B13) differs from Example 1 only in that the amine compound in step (3) is replaced with an equimolar amount of 3-(aminomethyl)pyrazole, yielding a gray solid compound B13 with a yield of 85%.
[0093] The obtained compound B13 was identified using nuclear magnetic resonance spectroscopy and mass spectrometry, and the results were as follows: 1 H NMR (400 MHz, DMSO- d 6) d 13.46 (s, 1H), 12.78 (s, 1H), 10.34 (s, 1H), 8.31-8.02 (m, 2H), 7.91 (d, J = 7.6 Hz, 1H), 7.73-7.63 (m, 3H), 7.36 (t, J = 7.6Hz, 1H), 6.31 (s, 1H), 4.69 (d, J = 5.2 Hz, 2H). 13 C NMR (101 MHz, DMSO- d 6) d165.0, 150.9, 147.5, 144.9, 143.7, 139.3, 135.5, 132.6, 131.7 (t, J = 255.2 Hz, -CF2), 125.2, 124.8, 123.6, 122.1, 122.0, 116.1, 111.2, 109.4, 104.2, 36.6. ESI-HRMS m / z: Calculated value is C 19 H 14 F2N5O3 + [M + H] + , 398.1059; The measured value is 398.1063.
[0094] Example 29 A method for preparing a benzimidazole compound (compound B14) differs from Example 1 only in that the amine compound in step (3) is replaced with an equimolar amount of 4-fluoro-3-methylbenzylamine, yielding a white solid compound B14 with a yield of 77%.
[0095] The obtained compound B14 was identified using nuclear magnetic resonance spectroscopy and mass spectrometry, and the results were as follows: 1 H NMR (400 MHz, DMSO- d 6) d 13.49 (s, 1H), 10.25 (t, J = 5.6 Hz, 1H), 8.20 (s, 1H), 8.07 (d, J = 8.4 Hz, 1H), 7.91 (d, J = 7.6 Hz, 1H), 7.75 (d, J = 8.0 Hz, 1H), 7.64 (d, J = 8.4 Hz, 1H), 7.38 (t, J = 7.6 Hz, 2H), 7.33-7.22 (m, 1H), 7.12 (t, J = 9.2 Hz, 1H), 4.65 (d, J = 5.6 Hz, 2H), 2.23 (d, J = 2.0 Hz, 3H). 13 C NMR (101MHz, DMSO- d 6) d 164.9, 160.2 (d, J= 242.6 Hz, -CF), 150.6, 145.4, 143.7, 136.8,135.6 (d, J = 3.3 Hz), 134.8, 131.7 (t, J = 255.7 Hz, -CF2), 130.9 (d, J = 5.2 Hz), 126.9 (d, J = 8.2 Hz), 125.5, 124.5 (d, J = 17.2 Hz), 124.3, 124.0, 123.5, 122.0,116.5, 115.1 (d, J = 22.2 Hz), 111.1, 110.1, 42.5, 14.5. ESI-HRMS m / z: Calculated value is C 23 H 17 F3N3O3 + [M + H] + , 440.1216; The measured value is 440.1216.
[0096] Example 30 A method for preparing a benzimidazole compound (compound B15) differs from Example 1 only in that the amine compound in step (3) is replaced with an equimolar amount of 2-(aminomethyl)pyrimidine, yielding a gray solid compound B15 with a yield of 81%.
[0097] The obtained compound B15 was identified using nuclear magnetic resonance spectroscopy and mass spectrometry, and the results were as follows: 1 H NMR (400 MHz, TFA- d ) d 9.37-9.28 (m, 2H), 8.29-8.01 (m, 3H), 8.01-7.91 (m, 1H), 7.86 (q, J = 5.6, 4.8 Hz, 1H), 7.77 (p, J = 8.4 Hz, 1H), 7.51-7.09 (m, 1H), 5.34 (s, 2H), NH (not observed, 2H). 13 C NMR (101 MHz, TFA- d ) d163.5,153.9 (2×C), 146.4, 144.7, 140.9, 127.8, 127.5 (t, J = 259.1 Hz, -CF2), 125.8, 123.1, 121.8, 121.4, 118.0, 115.0, 113.0, 111.7, 106.5, 105.8, 104.9, 38.8. ESI-HRMS m / z: Calculated value is C 20 H 14 F2N5O3 + [M + H] + , 410.1059; The measured value is 410.1061.
[0098] Example 31 A method for preparing a benzimidazole compound (compound B16) differs from Example 1 only in that the amine compound in step (3) is replaced with an equimolar amount of 3,5-difluorobenzylamine, yielding a gray solid compound B16 with a yield of 76%.
[0099] The obtained compound B16 was identified using nuclear magnetic resonance spectroscopy and mass spectrometry, and the results were as follows: 1 H NMR (400 MHz, DMSO- d 6) d 13.50 (s, 1H), 10.28 (t, J = 6.0 Hz, 1H), 8.31 (s, 1H), 8.12 (d, J = 8.4 Hz, 1H), 7.89 (d, J = 7.6 Hz, 1H), 7.76 (d, J = 8.0 Hz, 1H), 7.62 (d, J = 8.4 Hz, 1H), 7.37 (t, J = 7.6 Hz, 1H), 7.18-7.08 (m, 3H), 4.74 (d, J = 5.6 Hz, 2H). 13 C NMR (101 MHz, DMSO- d 6) d 165.3, 162.9 (dd, J = 247.1, 13.2Hz, -CF, 2×C), 151.0, 145.1, 145.0 (td, J= 9.2, 2.1 Hz), 143.7, 138.7, 135.4,131.7 (t, J = 255.2 Hz, -CF2), 125.0, 124.8, 123.8, 123.8, 122.0, 116.4, 111.1,110.6 (dd, J = 18.6, 6.8 Hz, 2×C), 109.8, 102.6 (t, J = 25.8 Hz), 42.6. ESI-HRMSm / z: Calculated value is C 22 H 14 F4N3O3 + [M + H] + , 444.0966; The measured value is 444.0967.
[0100] Example 32 A method for preparing a benzimidazole compound (compound B17) differs from Example 1 only in that the amine compound in step (3) is replaced with an equimolar amount of o-fluorobenzylamine, yielding a pale yellow solid compound B17 with a yield of 89%.
[0101] The obtained compound B17 was identified using nuclear magnetic resonance spectroscopy and mass spectrometry, and the results were as follows: 1 H NMR (400 MHz, DMSO- d 6) d 13.48 (s, 1H), 10.33 (t, J = 6.0 Hz, 1H), 8.19 (s, 1H), 8.07 (d, J = 8.4 Hz, 1H), 7.89 (d, J = 7.6 Hz, 1H), 7.74 (d, J = 8.0 Hz, 1H), 7.62 (d, J = 8.4 Hz, 1H), 7.48 (t, J = 7.6 Hz, 1H), 7.38-7.31 (m, 2H), 7.25-7.16 (m, 2H), 4.76 (d, J = 5.6 Hz, 2H). 13 C NMR (101 MHz, DMSO- d 6) d 165.0, 160.7 (d, J= 244.9 Hz, -CF), 150.9, 145.1, 143.7, 138.7, 135.4, 131.7, 129.9 (d, J =4.3 Hz), 129.5 (d, J = 8.3 Hz), 126.5 (d, J = 14.8 Hz), 124.9, 124.8, 124.8,123.8 (d, J = 8.3 Hz), 122.0, 121.9, 116.3, 115.6 (d, J = 21.2 Hz), 111.1, 109.6, 37.2. ESI-HRMS m / z: Calculated value is C 22 H 15 F3N3O3 + [M + H] + , 426.1060; The measured value is 426.1060.
[0102] Example 33 A method for preparing a benzimidazole compound (compound B18) differs from Example 1 only in that the amine compound in step (3) is replaced with an equimolar amount of 1-tert-butoxycarbonyl-4-aminomethylpiperidine, yielding a gray solid compound B18 with a yield of 78%.
[0103] The obtained compound B18 was identified using nuclear magnetic resonance spectroscopy and mass spectrometry, and the results were as follows: 1 H NMR (400 MHz, DMSO- d 6) d 13.47 (s, 1H), 9.90 (t, J = 6.0 Hz, 1H), 8.18 (s, 1H), 8.07 (d, J = 8.4 Hz, 1H), 7.87 (d, J = 7.6 Hz, 1H), 7.73 (d, J = 8.0 Hz, 1H), 7.65 (d, J = 8.4 Hz, 1H), 7.35 (t, J = 7.6 Hz, 1H), 3.98 (d, J = 13.2 Hz, 2H), 3.37 (d, J= 12.0 Hz, 2H), 2.73 (s, 2H), 1.98-1.80 (m, 1H), 1.76 (d, J = 14.0 Hz, 2H), 1.35 (s, 9H), 1.26-1.12 (m, 2H). 13 C NMR (101 MHz, DMSO- d 6) d 164.9, 154.3,150.6, 145.4, 143.7, 136.8, 134.7, 131.7 (t, J = 255.7 Hz, -CF2), 125.4, 124.3, 123.9, 123.6, 122.3, 116.3, 111.1, 109.9, 78.8, 44.7, 43.6, 36.4 (2×C), 30.0 (2×C), 28.3 (3×C). ESI-HRMS m / z: Calculated value is C 26 H 29 F2N4O5 + [M + H] + , 515.2100; The measured value is 515.2100.
[0104] Technical effects: 1. Anti-inflammatory activity tests of various compounds 1.1. Cell Culture Human ovarian granulosa cells (KGN) were cultured in DMEM / F12 medium (Gibco, catalog number: A41920-01) supplemented with 10% (v / v) FBS (Gibco, catalog number: 10270-106), 100 U / mL penicillin, and 100 μg / mL streptomycin (Gibco, catalog number: 15140122). The culture conditions were 37 ℃ and 5% CO2. Cells were passaged when they reached 80% confluence.
[0105] 1.2. Cytotoxicity Detection KGN cells were selected, at a concentration of 2 × 10⁻⁶. 4The cells were seeded at a density of 100 μL / well in 96-well plates. When the cell coverage was about 80%, compounds A1-A15 and B1-B18 were added to each well (to a concentration of 10 μM, the same below). Each group had 3 replicates. A normal group was also set up (DMSO solvent was used instead of the equimolar amount of the compounds obtained in the example). After culturing for 24 h, 10 μL of CCK8 solution was added to each well. The cells were incubated at 37°C in a 5% CO2 incubator for another 2 h. The absorbance (OD) value was measured at 450 nm using a microplate reader, and the cell inhibition rate was calculated.
[0106] The results are as follows Figure 1 As shown, except for A1, A2, A5, A6, A7, A8, A9, and B5, none of the synthesized compounds showed obvious toxicity.
[0107] 1.3. Screening of anti-apoptotic compounds KGN cells at 2×10 5 The cells were seeded at a density of 1 mL / well in 12-well plates. When the cell coverage was about 80%, compounds A3, A4, A10-A15 and compounds B1-B4, B6-B18 (final concentration of compounds 10 μM) obtained in Examples 3, 4 and 10-33 were added. DMSO solvent was used as the control group instead of equimolar amounts of the compounds obtained in the examples. After 2 h, cyclophosphamide (CTX) at a final concentration of 250 μM was added to continue stimulation for 24 h.
[0108] Among them, the group that treated KGN cells with the compounds obtained in the examples for 2 hours and then continued to be stimulated with cyclophosphamide was designated as the treatment group, and each compound was identified by its serial number in the attached figure; The group in which KGN cells were treated with DMSO solvent instead of an equimolar amount of the compound obtained in the example for 2 hours, and then cyclophosphamide was added for further stimulation, was designated as the cyclophosphamide group. (1) RNA extraction and qPCR assay After completely discarding the culture medium from the cultured cells, add 0.5 mL of RL from the RNA extraction kit to each well for lysis; collect the cell lysate and extract Total RNA according to the kit instructions (Vazyme, catalog number: RC112), and measure its concentration using an ultra-micro UV-Vis spectrophotometer. (2) Reverse transcription reaction A 20 μL reverse transcription system was established, including 4 μL of 5×Buffer, 500 ng (X μL) of Total RNA, and 8 μL of DEPC-H2O (16-X). The tubes were labeled and placed in a PCR instrument at 50 °C for 15 min and 85 °C for 5 s for reverse transcription. (3) Quantitative fluorescence Add 80 μL DEPC-H2O to the transcribed cDNA to a final volume of 100 μL, centrifuge to mix, and store at -20℃. Take 18 μL of the mixture (SYBR 10 μL + DEPC-H2O 10 μL + primer 0.5 μL) multiplied by the number of samples and transfer it to a 96-well plate. Add 2 μL of cDNA to make a 20 μL mixture, centrifuge at 1200 rpm for 1 min to mix. Place the sample plate in a CFXConnect Real-Time PCR system for detection. Cycle 39 times at 95℃ for 2 min; 95℃ for 20 s; 57℃ for 20 s; 72℃ for 20 s. Then, perform the detection using the following program: 95℃ for 1 min; 55℃ for 30 s; 95℃ for 30 s. (4) Analysis Use 2 ‑ΔΔCt The experimental results were analyzed using the following formula: △Ct target gene = Ct target gene - Ct internal reference gene.
[0109] △△Ct target gene = △Ct experimental group target gene - △Ct control group target gene.
[0110] 2 ‑ΔΔCt This indicates the fold increase in the expression of the target gene in the experimental group compared to the control group.
[0111] The primers are shown in Table 1 below.
[0112] Table 1 Primer Sequences The filtering results are as follows Figure 2 As shown. The comparison between the cyclophosphamide group and the normal group... *** P <0.001; Comparison between the drug-treated group and the cyclophosphamide group ### P <0.001, compound A12 exhibited the best anti-apoptotic activity.
[0113] 2. In vitro evaluation of compound A12 2.1. Cytotoxicity Detection Similar to Section 1.2 above, the difference is that only different concentrations (1, 3, 5, 10, 20, 60 μM) of compound A12 were added. A normal group was also set up (the compound obtained in the examples was replaced with DMSO solvent in equimolar amounts). The absorbance (OD value) was measured at 450 nm using a microplate reader, and the cell inhibition rate was calculated. The results are as follows: Figure 3 As shown, compound A12 did not exhibit significant toxicity at different concentrations.
[0114] 2.2. Inhibition test of the compound on the expression levels of inflammatory factors and apoptosis factors.
[0115] The procedure is the same as in section 1.3 above, except that the compounds used are only compound 12 at different concentrations (0.5, 1.0, 1.5, 2.0 μM). Primers are shown in Table 1.
[0116] The results are as follows Figure 4 As shown, in CTX-induced KGN cells, compound A12 inhibited the secretion of Bax, IL-1β, and IL-6 in a concentration-dependent manner, with Bax having an IC50 value of [missing value]. 50 The IC50 of IL-1β was 1.65 μM (A). 50 The IC of IL-6 is 1.66 μM (B). 50 The value was 1.63 μM (C).
[0117] 2.3. Effects of the compound on the expression levels of inflammatory factors, apoptosis factors, and aging-related factors.
[0118] The procedure was the same as in section 1.3 above, except that the compound was only compound A12 at a concentration of 2 μM. Estradiol at a final concentration of 10 μM was used to replace compound A12 as a positive control group, and DMSO solvent was used to replace the equimolar amount of the compound obtained in the previous example as a normal group. After 2 h, CTX at a final concentration of 250 μM was added to continue stimulation for 24 h.
[0119] Among them, the group that treated KGN cells with the compound obtained in the example for 2 hours and then continued to be stimulated with cyclophosphamide was designated as the treatment group (corresponding to group A12 in the attached figure). The group that treated KGN cells with the positive control drug for 2 hours and then continued to be stimulated with cyclophosphamide was designated as group E2. The group in which KGN cells were treated with DMSO solvent instead of an equimolar amount of the compound obtained in the example for 2 hours, and then cyclophosphamide was added for further stimulation, was designated as the cyclophosphamide group. The primers are shown in Table 1.
[0120] The anti-inflammatory properties of compound A12, such as Figure 5 As shown in the figure, it can be seen that the cyclophosphamide group and the normal group are compared * P <0.05, *** P <0.001; Comparison between the drug-treated group and the cyclophosphamide group ,# P <0.05, ## P <0.01, ### P<0.001. Compared with the control group, CTX stimulation increased the mRNA expression of inflammatory factors, especially IL-6 (A) and IL-1β (B). In CTX-induced KGN cells, compound A12 significantly increased the expression of IL-4 (C) and IL-10 (D), while significantly decreasing the expression of IL-6 and IL-1β. These results indicate that compound A12 has excellent anti-inflammatory activity.
[0121] The anti-apoptotic ability of compound A12 is as follows Figure 6 As shown in the figure, it can be seen that the cyclophosphamide group and the normal group are compared *** P <0.001; Comparison between the drug-treated group and the cyclophosphamide group ### P <0.001, in CTX-stimulated KGN cells, the expression of Caspase3 (A) and Bax (B) was significantly increased. This upregulation could be partially or completely reversed by compound A12, indicating that compound A12 can inhibit CTX-induced excessive apoptosis.
[0122] The anti-aging ability of compound A12 is as follows Figure 7 As shown in section AC, after CTX stimulation, the expression of CDKN1A (A) and CDKN2A (B) in KGN cells was significantly increased, while the expression of LAMP2 (C) was slightly decreased. After treatment with compound A12, the expression of CDKN1A and CDKN2A in CTX-induced KGN cells was significantly reduced, and the expression of LAMP2 was restored to a level comparable to that of the control group.
[0123] 2.4. The reversal effect of compounds on aging KGN cells were selected, at a concentration of 2 × 10⁻⁶. 5 KGN cells were seeded at a density of 1000 μL / well in 12-well plates. When the cell coverage was approximately 80%, compound A12 (final concentration 2 μM) and the positive control drug (estradiol, final concentration 10 μM) were added. A normal group was also set up (DMSO solvent was used to replace an equimolar amount of compound A12). The cells were cultured for another 2 h, and then stimulated with CTX for 24 h to obtain cultured cells. The group that treated KGN cells with the compound obtained in the example for 2 h and then continued to be stimulated with cyclophosphamide was designated as the treatment group (corresponding to the A12 group in the attached figure). The group that treated KGN cells with the positive control drug for 2 hours and then continued to be stimulated with cyclophosphamide was designated as group E2. The group in which KGN cells were treated with DMSO solvent instead of an equimolar amount of the compound obtained in the example for 2 hours, and then cyclophosphamide was added for further stimulation, was designated as the cyclophosphamide group. The cultured cells were then stained with senescence-associated β-galactosidase (SA-β-Gal), specifically including the following steps: (1) Discard the culture medium completely after the cells have been cultured, wash the cells gently twice with PBS, and then add an appropriate amount of fixative (about 1 mL per well in a 6-well plate) and fix at room temperature for 15 minutes. After that, discard the fixative and wash the cells three more times with PBS for 3 minutes each time.
[0124] (2) Add staining solution: Add 1 mL of freshly prepared SA-β-Gal staining working solution to each well of a 6-well plate and incubate overnight in a 37°C incubator. Once the color develops to blue, discard the staining solution, add PBS to terminate the reaction, and observe and photograph using an optical microscope.
[0125] Staining results as follows Figure 7 As shown in section DE, it can be seen that the cyclophosphamide group and the normal group... * P <0.05, ** P <0.01, *** P <0.001; Comparison between the drug-treated group and the cyclophosphamide group ,# P <0.05, ## P <0.01 indicates mild senescence in the normal group cells, while the percentage of SA-β-gal positive cells in the cyclophosphamide group is significantly increased. This condition was partially reversed by compound A12. These results suggest that compound A12 has anti-aging effects.
[0126] 2.5. Detection of PCNA Expression Levels by Compounds KGN cells were selected, at a concentration of 2 × 10⁻⁶. 5 KGN cells were seeded at a density of 1000 μL / well in confocal dishes. When the cell coverage was approximately 80%, compound A12 (2 μM) and the positive control drug (estradiol, final concentration 10 μM) were added, and a normal group was set up (DMSO solvent was used to replace an equimolar amount of compound A12). The cells were cultured for another 24 h, and then stimulated with CTX for 24 h for immunofluorescence. The group that was treated with the compound obtained in the example for 2 h and then stimulated with cyclophosphamide was designated as the treatment group (corresponding to the A12 group in the attached figure). The group that treated KGN cells with the positive control drug for 2 hours and then continued to be stimulated with cyclophosphamide was designated as group E2. The group in which KGN cells were treated with DMSO solvent instead of an equimolar amount of the compound obtained in the example for 2 hours, and then cyclophosphamide was added for further stimulation, was designated as the cyclophosphamide group. Immunofluorescence specifically includes the following steps: (1) KGN cells were fixed with 4% paraformaldehyde for 30 min, and then the confocal dish was washed with PBS for 5 min. This was repeated three times. Cells were permeabilized with PBST for 20 min, and then the confocal dish was washed with PBS for 5 min. This was repeated three times. (2) The primary antibody PCNA (10205-2-AP, Proteintech) was added to the cells covered in step (1), and the cells were incubated overnight at 4°C on a shaker. The confocal dish was then washed with PBS for 5 min, and this process was repeated three times to complete the incubation of the primary antibody. The secondary antibody with fluorescent labeling was then added to the cells covered in the primary antibody, and the cells were incubated at 37°C for 1 h. The confocal dish was then washed with PBS for 5 min, and this process was repeated three times to complete the incubation of the secondary antibody. (3) staining the nuclei: DAPI was added to cover the cells obtained in step (2), and the cells were incubated at 37°C for 10 min. The confocal dish was then washed with PBS for 5 min. This process was repeated three times. The cells were then placed under a microscope to observe the pathological changes, and photographed and analyzed.
[0127] The results are as follows Figure 8 As shown in the figure, it can be seen that the cyclophosphamide group and the normal group are compared * P <0.05; comparison between the drug-treated group and the cyclophosphamide group ### P <0.001, in KGN cells, PCNA expression was significantly decreased in the LPS group compared to the Control group; PCNA expression was significantly increased in the compound A12 group compared to the LPS group, indicating that the compound can promote cell proliferation.
[0128] The above are merely preferred embodiments of the present invention, but the scope of protection of the present invention is not limited thereto. Any variations or substitutions that can be easily conceived by those skilled in the art within the scope of the technology disclosed in the present invention should be included within the scope of protection of the present invention. Therefore, the scope of protection of the present invention should be determined by the scope of the claims.
Claims
1. A benzimidazole compound, characterized in that, The structural formula is shown in equation (I): (I); Wherein, L is one of -C2H4- or -CF2-; The R is independently selected from , , , , , , , , , , , , , , , , , , , , , , , or One of them.
2. A method for preparing a benzimidazole compound as described in claim 1, characterized in that, Includes the following steps: (1) Using aryl aldehydes as raw materials, methyl 2,3-diaminobenzoate was reacted with benzimidazole condensation cyclization in a solvent to obtain intermediate A. Then, saponification was carried out under alkaline conditions. After the reaction was completed, the pH was adjusted to weak acidity to obtain intermediate B. The aryl aldehyde compounds are Wherein, L is one of -C2H4- or -CF2-; (2) The intermediate B is subjected to an amidation reaction with an amine compound in the presence of a condensing agent and a base to obtain the benzimidazole compound shown in Formula I.
3. The preparation method according to claim 2, characterized in that, The benzimidazole condensation cyclization reaction in step (1) uses sodium metabisulfite as a promoter, the reaction temperature is 80℃, and the reaction time is 16h.
4. The preparation method according to claim 2, characterized in that, The solvent mentioned in step (1) is DMF.
5. The preparation method according to claim 2, characterized in that, The alkaline hydrolysis reagent used in the alkaline conditions described in step (1) is LiOH; The saponification reaction takes 4 hours.
6. The preparation method according to claim 2, characterized in that, The step (1) of adjusting the pH to weak acidity is to use dilute hydrochloric acid to adjust the pH to 6.
7. The preparation method according to claim 2, characterized in that, The amine compounds mentioned in step (2) include one of the following: 3-aminopyridazine, 5-amino-1,3-dimethylpyrazole, 2-aminothiazole, 2-(aminomethyl)naphthalene, 3-(aminomethyl)pyrazole, 3,5-difluorobenzylamine, 1-tert-butoxycarbonyl-4-aminomethylpiperidine, 2,6-dimethylaniline, 2-(aminomethyl)pyridine, benzylamine, 2-(aminomethyl)pyrimidine, 4-aminomethyltetrahydropyran, 5-aminobenzothiazole, cyclopropylamine, 2,6-dichlorobenzylamine, o-fluorobenzylamine, 3,4-difluorobenzylamine, 3-(imidazol-1-yl)propyl-1-amine, 3,4-dimethoxyphenethylamine, 4-fluoro-3-methylbenzylamine, 4-methylbenzylamine, and methyl 4-(aminomethyl)benzoate.
8. The preparation method according to claim 2, characterized in that, The condensing agent mentioned in step (2) is 2-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethylurea hexafluorophosphate; The base is N,N-diisopropylethylamine.
9. The preparation method according to claim 2, characterized in that, The amidation reaction in step (2) takes 4 hours.
10. The use of a benzimidazole compound as described in claim 1 in the preparation of a medicament for treating early-onset ovarian hypoplasia.
